CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing a combined therapy for metastatic melanoma using magnetic nanoparticles to enhance the infiltration of chimeric antigen receptor T cells. By applying magnetic and optical hyperthermia, it aims to disrupt the tumor microenvironment, facilitating more effective treatment of this challeng…
Metastatic melanoma is a hard-to-treat disease and it remains as one of the most worrisome cancer.
There is an urgent need to improve the current therapies (chemotherapy, radiotherapy) that have a limited efficacy. A single therapy is not efficient to tackle metastatic melanoma and a combination of therapies is thus emerging as a necessity to efficiently eradicate all cancer cells.
Recently, the development of immunotherapies has shown promises, in particular chimeric antigen receptor (CAR)-T ce…
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Cyprus, Nicosia
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Finland, Turku
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
